Axogen, Inc. (AXGN), is a leading medical technology company operating in the field of regenerative medicine. The company is devoted to revolutionizing the field of nerve repair and regeneration, placing emphasis on restoring the quality of life of individuals who suffer from peripheral nerve injuries (PNI) via the provision of innovative, high-quality medical products. Axogen's mission is to eradicate the debilitating consequences of PNI.
Established in 2002, Axogen, Inc. is headquartered in Alachua, Florida, but its presence extends across the globe. Today, it remains the only company to provide a broad range of clinically proven and scientifically backed products that assist in the repair and regeneration of peripheral nerves.
The product portfolio of Axogen includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site. Axoguard® Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves. Axoguard® Nerve Protector, a porcine submucosa extracellular matrix to reinforce the nerve reconstruction while preventing soft tissue attachments. Axotouch™ Two-Point Discriminator (TPD), a tool used to measure two-point discrimination, all of these are revolutionizing the science of nerve repair.
The company places a significant value on research and innovation. Its dynamic and constantly evolving infrastructure is tangible evidence of the same. Axogen maintains an ethos of perpetual learning, prioritizing the continuous advancement of medical science, and developing products that are evidence-based.
Axogen, Inc. holds a strong competitive position given its monopoly in the field of peripheral nerve regeneration. It's not only fostering a diverse offering of unique products and services, but it also maintains a robust pipeline of innovations, signifying its commitment to expanding the scope and penetration of nerve repair solutions.
Their dedication to patient satisfaction and ensuring the best healthcare outcomes is evident in their strategies for patient and physician education. They proactively provide training and educational courses for surgeons and medical staff, allowing for increased understanding and proficient use of their products.
Overall, Axogen, Inc. is leading the way in the development of new technologies in nerve repair, answering a global health challenge. Through dedication to innovation and patient care, Axogen maintains a formidable position in the regenerative medicine market. They command admiration for their work towards restoring functionality and improving the quality of life for individuals suffering from peripheral nerve injuries.